MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Triple Helix Framework
Industry
Architects: Small & Medium Size Business (SMBs), Product Development, De-Risking, Validation, Building Niche & Emerging Markets
Architects: Biotechnology_Stem Cell Therapeutics
Cell BioEngines, Inc.
Attachments
Cell BioEngines: Off-the-Shelf Curative Cell Therapies
Parents
*Industry: New York City
2026: Defense TechConnect Innovation Spotlights: Biotech and Health Security I
Architects: Biotechnology_Stem Cell Therapeutics
Children
*A defense angle could be bone marrow failure after radiation exposure
*A donor-independent, scalable stem cell supply would ease a real transplant bottleneck.
*Allogeneic 'off-the-shelf' cell therapies as ‘drugs’
*Cell BioEngines is a platform company with a proprietary manufacturing process that chemically reprograms cord blood stem cells to produce mass stem cells (100x) and immune cell supply (1000x) of off-the-shelf blood products without gene editing.
*Chemically reprogramming stem cell
*Lead product, CBE-101, targets blood cancer patients who can't find a donor for haploidentical transplant.
*Moving from 'one dose per patient' to 'hundreds of doses per unit.
*Starts from universal umbilical cord blood stem cells and expands, differentiates and de-differentiates them to produce cells at large scale, paired with an AI platform that predicts donor availability and HLA compatibility.
Founded 2022
New York City, New York